ATE129160T1 - Herpes-simplex-impfstoff, der hsv-glycoprotein-gd und 3-deacyl monophosphoryl-lipid-a enthaelt. - Google Patents

Herpes-simplex-impfstoff, der hsv-glycoprotein-gd und 3-deacyl monophosphoryl-lipid-a enthaelt.

Info

Publication number
ATE129160T1
ATE129160T1 AT92906441T AT92906441T ATE129160T1 AT E129160 T1 ATE129160 T1 AT E129160T1 AT 92906441 T AT92906441 T AT 92906441T AT 92906441 T AT92906441 T AT 92906441T AT E129160 T1 ATE129160 T1 AT E129160T1
Authority
AT
Austria
Prior art keywords
herpes simplex
monophosphoryl lipid
vaccine containing
hsv glycoprotein
containing hsv
Prior art date
Application number
AT92906441T
Other languages
English (en)
Inventor
Myriam Francotte
Jean-Paul Prieels
Moncef Slaoui
Nathalie Marie- Garcon-Johnson
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10691946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE129160(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Application granted granted Critical
Publication of ATE129160T1 publication Critical patent/ATE129160T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT92906441T 1991-03-21 1992-03-17 Herpes-simplex-impfstoff, der hsv-glycoprotein-gd und 3-deacyl monophosphoryl-lipid-a enthaelt. ATE129160T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9105992A GB9105992D0 (en) 1991-03-21 1991-03-21 Vaccine

Publications (1)

Publication Number Publication Date
ATE129160T1 true ATE129160T1 (de) 1995-11-15

Family

ID=10691946

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92906441T ATE129160T1 (de) 1991-03-21 1992-03-17 Herpes-simplex-impfstoff, der hsv-glycoprotein-gd und 3-deacyl monophosphoryl-lipid-a enthaelt.

Country Status (34)

Country Link
US (1) US6027730A (de)
EP (1) EP0576478B2 (de)
JP (1) JP3530526B2 (de)
KR (1) KR100224329B1 (de)
CN (2) CN1058191C (de)
AP (1) AP298A (de)
AT (1) ATE129160T1 (de)
AU (1) AU650521B2 (de)
BR (1) BR9205745A (de)
CA (1) CA2106492C (de)
CY (1) CY1936A (de)
CZ (1) CZ280505B6 (de)
DE (1) DE69205566T3 (de)
DK (1) DK0576478T4 (de)
ES (1) ES2081102T5 (de)
FI (1) FI107881B (de)
GB (1) GB9105992D0 (de)
GR (1) GR3017884T3 (de)
HK (1) HK1004525A1 (de)
HU (1) HU218025B (de)
IE (1) IE69560B1 (de)
IL (1) IL101290A (de)
MA (1) MA22471A1 (de)
MX (1) MX9201245A (de)
MY (1) MY110086A (de)
NO (1) NO307499B1 (de)
NZ (1) NZ242057A (de)
PL (1) PL170059B1 (de)
PT (1) PT100262B (de)
SA (1) SA92120459B1 (de)
SK (1) SK279190B6 (de)
WO (1) WO1992016231A1 (de)
YU (1) YU28392A (de)
ZA (1) ZA922011B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
US6197311B1 (en) 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
GB9202933D0 (en) * 1992-02-12 1992-03-25 Smithkline Beecham Biolog Vaccines
US6620414B2 (en) 1992-03-27 2003-09-16 Smithkline Beecham Biologicals (S.A.) Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
CA2156525A1 (en) * 1993-02-19 1994-09-01 Susan Dillon Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
PL178578B1 (pl) * 1993-03-23 2000-05-31 Smithkline Beecham Biolog Zawiesina cząstek 3-0-deacylowanego monofosforylolipidu A i sposób jej wytwarzania oraz kompozycja szczepionki zawierającej antygen w połączeniu z 3-0-deacylowanym monofosforylolipidem A i sposób jej wytwarzania
ES2150493T5 (es) * 1993-05-25 2004-07-01 Wyeth Holdings Corporation Adyuvantes para vacunas contra el virus sincitico respiratorio.
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JPH10511846A (ja) 1994-12-28 1998-11-17 ユニバーシティ オブ ケンタッキー ヒトガン胎児性抗原に関連する組換えモノクローナル抗イディオタイプ抗体３ｈ１配列
US6949244B1 (en) 1995-12-20 2005-09-27 The Board Of Trustees Of The University Of Kentucky Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US6235280B1 (en) 1996-04-12 2001-05-22 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US20020041872A1 (en) 1996-04-12 2002-04-11 Malaya Chatterjee Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6468782B1 (en) 1996-12-05 2002-10-22 Quadrant Healthcare (Uk) Limited Methods of preserving prokaryotic cells and compositions obtained thereby
US6274143B1 (en) 1997-06-13 2001-08-14 Malaya Chatterjee Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
GB9819898D0 (en) * 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
US6692752B1 (en) * 1999-09-08 2004-02-17 Smithkline Beecham Biologicals S.A. Methods of treating human females susceptible to HSV infection
CA2347099C (en) 1998-10-16 2014-08-05 Smithkline Beecham Biologicals S.A. Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof
US7026155B2 (en) 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
EP1104767A1 (de) 1999-11-30 2001-06-06 Stichting Dienst Landbouwkundig Onderzoek Mono- und Disaccharidederivate die sowohl Fettsäureestern als Sulfatestern enthalten
US9273326B2 (en) 2004-04-30 2016-03-01 The Brigham And Women's Hospital, Inc. Tetracycline-regulated gene expression in HSV-1 vectors
NZ553776A (en) 2004-09-22 2010-05-28 Glaxosmithkline Biolog Sa Immunogenic composition comprising staphylococcal PNAG and Type 5 and/or 8 Capsular polysaccharide or oligosaccharide.
CA2601022C (en) 2005-03-23 2023-03-07 Glaxosmithkline Biologicals S.A. Use of an influenza virus an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
EP3020411A1 (de) 2005-12-22 2016-05-18 GlaxoSmithKline Biologicals s.a. Impfstoff
EP1998802A2 (de) 2006-03-30 2008-12-10 GlaxoSmithKline Biologicals S.A. Immunogene zusammensetzung
JP5639760B2 (ja) 2006-07-17 2014-12-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザワクチン
DK2068918T4 (da) 2006-09-26 2024-09-02 Access To Advanced Health Inst Vaccinesammensætning omfattende syntetisk adjuvant
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
TW200908994A (en) 2007-04-20 2009-03-01 Glaxosmithkline Biolog Sa Vaccine
PT2167121E (pt) 2007-06-26 2015-12-02 Glaxosmithkline Biolog Sa Vacina compreendendo conjugados de polissacáridos capsulares de streptococcus pneumoniae
EP3590533A1 (de) 2009-05-22 2020-01-08 Genocea Biosciences, Inc. Impfstoffe gegen den herpes-simplex-virus vom typ 2: zusammensetzungen und verfahren zur auslösung einer immunreaktion
EP3124491B1 (de) * 2009-06-05 2019-10-30 Infectious Disease Research Institute Synthetische glucopyranosyl-lipid-adjuvanzien und impfstoffzusammensetzungen sowie pharmazeutische zusammensetzungen die diese enthalten
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
RS54933B1 (sr) 2009-12-21 2016-10-31 Brigham & Womens Hospital Inc Vakcine herpes simpleks virusa
EP2643014A4 (de) 2010-11-24 2015-11-11 Genocea Biosciences Inc Impfstoffe gegen den herpes-simplex-virus vom typ 2: zusammensetzungen und verfahren zur auslösung einer immunreaktion
CN108126204A (zh) * 2011-03-11 2018-06-08 特斯通有限责任合伙公司 包含组蛋白去乙酰化酶抑制剂的疫苗接种方法
JP6054942B2 (ja) 2011-04-08 2016-12-27 イミューン デザイン コーポレイション 免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法
CA2845872C (en) 2011-08-22 2023-03-28 Nanobio Corporation Herpes simplex virus nanoemulsion vaccine
CA2885693C (en) 2011-11-23 2020-07-28 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
CN107540730B (zh) 2012-05-16 2021-07-16 免疫设计公司 用于hsv-2的疫苗
DK2941269T3 (da) 2013-01-07 2021-01-11 Mucosal Vaccine Tech Llc Terapeutiske vacciner til behandling af herpes simplex-virus type 2-infektioner
BR112015025709A2 (pt) 2013-04-18 2017-07-18 Immune Design Corp monoterapia com gla para uso em tratamento de câncer
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
WO2018064232A1 (en) 2016-09-28 2018-04-05 Genocea Biosciences, Inc. Methods and compositions for treating herpes
WO2019152821A1 (en) 2018-02-05 2019-08-08 The Brigham And Women's Hospital, Inc. Recombinant herpes simplex virus-2 expressing glycoprotein b and d antigens
WO2022152939A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4372945A (en) * 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) * 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US5110587A (en) * 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4762708A (en) * 1982-02-18 1988-08-09 University Patents, Inc. Materials and methods for herpes simplex virus vaccination
US5149660A (en) * 1982-02-18 1992-09-22 University Patents, Inc. Diagnostic reagents relating to herpes simplex virus
NZ209308A (en) * 1983-08-30 1991-08-27 Genentech Inc Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US5244792A (en) * 1984-04-06 1993-09-14 Chiron Corporation Expression of recombinant glyoprotein B from herpes simplex virus
US5171568A (en) * 1984-04-06 1992-12-15 Chiron Corporation Recombinant herpes simplex gb-gd vaccine
US4877611A (en) * 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5554372A (en) * 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
EP0289550B1 (de) * 1986-10-20 1996-04-10 Chiron Corporation Impfstoff zur behandlung von hsv
US5149529A (en) * 1988-04-08 1992-09-22 Board Of Trustees Of Leland Chiron Corporation Compositions and treatment for herpes simplex
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NZ230424A (en) * 1988-08-25 1992-05-26 Liposome Co Inc Liposomal composition comprising an externally disposed antigen
EP0440742B1 (de) * 1988-10-27 1997-01-15 The Regents Of The University Of Minnesota Immunhilfsmittel aus Liposome enthaltend Lymphokin IL -2
US5597573A (en) * 1989-05-04 1997-01-28 Igen, Inc. Lipid-A analogs: new monosaccharide and disaccharide intermediates for eliciting therapeutic antibodies and for antitumor and antiviral activities
US5158939A (en) * 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
WO1991001146A1 (en) * 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
ES2144400T3 (es) * 1990-08-01 2000-06-16 Res Corp Technologies Inc Gen que codifica la gliproteina d del virus del herpes equino de tipo 1, su producto genico, anticuerpos y su utilizacion.
JP3005292B2 (ja) * 1990-08-02 2000-01-31 カイロン コーポレイション 単純ヘルペスウィルスのｖｐ１６のワクチン
GB9106048D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccines
US5196452A (en) * 1991-01-29 1993-03-23 Genelabs Incorporated Macrocyclic anti-viral compound and method
US5166173A (en) * 1991-01-29 1992-11-24 Genelabs Incorporated Method of treating herpes simplex virus infection
GB9105992D0 (en) * 1991-03-21 1991-05-08 Smithkline Beecham Biolog Vaccine
MA22842A1 (fr) * 1992-03-27 1993-10-01 Smithkline Beecham Biolog Procede de preparation de compositions de vaccin.
NZ253137A (en) * 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
CA2156525A1 (en) * 1993-02-19 1994-09-01 Susan Dillon Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
PL178578B1 (pl) * 1993-03-23 2000-05-31 Smithkline Beecham Biolog Zawiesina cząstek 3-0-deacylowanego monofosforylolipidu A i sposób jej wytwarzania oraz kompozycja szczepionki zawierającej antygen w połączeniu z 3-0-deacylowanym monofosforylolipidem A i sposób jej wytwarzania
ES2150493T5 (es) * 1993-05-25 2004-07-01 Wyeth Holdings Corporation Adyuvantes para vacunas contra el virus sincitico respiratorio.

Also Published As

Publication number Publication date
NO933343L (no) 1993-09-20
PT100262B (pt) 2001-05-31
AP9200368A0 (en) 1992-04-30
GB9105992D0 (en) 1991-05-08
DK0576478T4 (da) 2001-07-23
IE920881A1 (en) 1992-09-23
SK279190B6 (sk) 1998-07-08
DE69205566T3 (de) 2002-09-05
CZ280505B6 (cs) 1996-02-14
CN1101226C (zh) 2003-02-12
CN1201692A (zh) 1998-12-16
CZ195893A3 (en) 1994-07-13
CA2106492A1 (en) 1992-09-22
PL170059B1 (pl) 1996-10-31
IE69560B1 (en) 1996-10-02
EP0576478B2 (de) 2001-04-18
MY110086A (en) 1997-12-31
CN1058191C (zh) 2000-11-08
CY1936A (en) 1992-03-17
JPH06505727A (ja) 1994-06-30
BR9205745A (pt) 1994-10-18
AP298A (en) 1994-01-14
NO933343D0 (no) 1993-09-20
US6027730A (en) 2000-02-22
DE69205566D1 (en) 1995-11-23
EP0576478B1 (de) 1995-10-18
PT100262A (pt) 1993-06-30
EP0576478A1 (de) 1994-01-05
FI107881B (fi) 2001-10-31
HK1004525A1 (en) 1998-11-27
IL101290A0 (en) 1992-11-15
HU9302645D0 (en) 1994-01-28
GR3017884T3 (en) 1996-01-31
MX9201245A (es) 1992-10-01
DE69205566T2 (de) 1996-04-18
CN1065997A (zh) 1992-11-11
KR100224329B1 (ko) 1999-10-15
IL101290A (en) 1996-07-23
HUT67052A (en) 1995-01-30
AU1365792A (en) 1992-10-21
CA2106492C (en) 2003-12-09
FI934134A (fi) 1993-09-21
NO307499B1 (no) 2000-04-17
JP3530526B2 (ja) 2004-05-24
HU218025B (hu) 2000-05-28
FI934134A0 (fi) 1993-09-21
ES2081102T3 (es) 1996-02-16
NZ242057A (en) 1993-12-23
SK94693A3 (en) 1994-05-11
MA22471A1 (fr) 1992-10-01
DK0576478T3 (da) 1995-12-04
WO1992016231A1 (en) 1992-10-01
ES2081102T5 (es) 2001-09-01
SA92120459B1 (ar) 2005-06-14
ZA922011B (en) 1993-01-27
YU28392A (sh) 1994-11-15
AU650521B2 (en) 1994-06-23

Similar Documents

Publication Publication Date Title
ATE129160T1 (de) Herpes-simplex-impfstoff, der hsv-glycoprotein-gd und 3-deacyl monophosphoryl-lipid-a enthaelt.
CY2007015I1 (el) Εμβολιο ιου θηλωματος
DE3685847D1 (de) Infrarot projektoranordnung.
AP9100332A0 (en) Vaccines
OA08199A (en) Vaccine.
OA08200A (en) Vaccine.
CY2008005I2 (el) Εμβολιο κατα της παρωτιτιδας που περιεχει στελεχος ιου jeryl-lynn
EP0595970A4 (de) Verbesserter impfstoff.
EP0236487A4 (de) Virus-inaktivierung.
EP0266401A4 (de) Impfstoffe.
GB9125896D0 (en) Bicistronic viruses
HU9203976D0 (en) Vaccine based on modified herpes virus
EP0570462A4 (de) Abgeändertes interleukin-1beta.
GB8602706D0 (en) Non-linear optics
GB8602708D0 (en) Non-linear optics
ZA939564B (en) Vaccines.
GB9225535D0 (en) Bicistronic viruses
EP0225329A4 (de) Impfstoff ohne hilfsmittel.
EP0681480A4 (de) Recognin vakzine.
ZA924670B (en) Ccv vaccine
EP0621893A4 (de) Impfstoffe gegen den leukämievirus der katze.
FI923350A0 (fi) Foerfarande foer maerkning av substanser med teknetium eller renium.
DE3768117D1 (de) Transportsicherung.
GB9324964D0 (en) Viral vaccines
GB9305710D0 (en) Viral vaccines

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification